These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effects of allostimulation and cyclosporine therapy on cytotoxic antibody production in highly sensitized prospective renal transplant recipients. Weir MR; Shen SY; Dagher FJ; Bentley FR; Lesko LJ; Sadler JH Transplantation; 1988 Oct; 46(4):591-4. PubMed ID: 3051568 [No Abstract] [Full Text] [Related]
6. Alternative immunosuppressive strategies in the management of recipients of living related renal transplants. Hodge E; Banowsky L; Novick A; Lewis R; Streem S; Steinmuller D; Holzmann J; McFarlin L; Graneto D; Medendorp SV Transplant Proc; 1989 Feb; 21(1 Pt 2):1609-14. PubMed ID: 2652524 [No Abstract] [Full Text] [Related]
7. The improving prognosis after kidney transplantation. New strategies to overcome immunologic rejection. Levey AS Arch Intern Med; 1984 Dec; 144(12):2382-7. PubMed ID: 6391406 [TBL] [Abstract][Full Text] [Related]
8. Outcome of kidney transplantation in highly sensitized patients after donor-specific blood transfusion. Takahashi K; Yagisawa T; Tanabe I; Teraoka S; Hayasaka Y; Yasuo M; Fuchinoue S; Honda H; Toma H; Agishi T Transplant Proc; 1987 Oct; 19(5):3655-60. PubMed ID: 2960043 [No Abstract] [Full Text] [Related]
9. A prospective study of prophylactic ATG versus cyclosporine in regrafted and highly sensitized renal allograft recipients. Pearson RC; Johnson RW; Bakran A; Dyer P; Martin S; O'Donoghue D; Scott PD Transplantation; 1990 Dec; 50(6):1061-3. PubMed ID: 2256151 [No Abstract] [Full Text] [Related]
10. Prolongation of renal allograft survival in DLA-tissue typed beagles after third-party leucocyte and erythrocyte transfusion. Obertop H; Bijnen AB; Schreve RH; Westbroek DL Proc Eur Dial Transplant Assoc; 1979; 16():366-71. PubMed ID: 398508 [TBL] [Abstract][Full Text] [Related]
11. Omission of donor-recipient crossmatching to minimize cold ischemia time in cadaveric renal transplantation. Fehrman I; Groth CG; Lundgren G; Möller E; Tydén G; Ost L Transplant Proc; 1987 Feb; 19(1 Pt 1):808-10. PubMed ID: 3547844 [No Abstract] [Full Text] [Related]
13. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]
14. Local use of kidneys with poor HLA matches is as good as shared use with good matches in the cyclosporine era: an analysis at one and two years. Alexander JW; Vaughn WK; Pfaff WW Transplant Proc; 1987 Feb; 19(1 Pt 1):672-4. PubMed ID: 3274836 [No Abstract] [Full Text] [Related]
19. Importance of HLA matching in highly sensitised renal transplant recipients with high transplant survival rates. The Manchester Kidney Transplant Team. Martin S; Connolly J; Jos V Transplant Proc; 1993 Feb; 25(1 Pt 1):265-6. PubMed ID: 8438295 [No Abstract] [Full Text] [Related]
20. Cyclosporine A, hyperimmunized patients, and renal retransplantation. Hendriks GF; de Lange P; Persijn GG; van Rood JJ Transplant Proc; 1987 Feb; 19(1 Pt 1):733-4. PubMed ID: 3274857 [No Abstract] [Full Text] [Related] [Next] [New Search]